

Ivan Rychlik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428589/publications.pdf>

Version: 2024-02-01

64
papers

3,838
citations

218592

26
h-index

128225

60
g-index

66
all docs

66
docs citations

66
times ranked

5163
citing authors

#	ARTICLE	IF	CITATIONS
1	A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. <i>Kidney International</i> , 2022, 101, 349-359.	2.6	10
2	Can Renal Parameters Predict the Mortality of Hospitalized COVID-19 Patients?. <i>Kidney and Blood Pressure Research</i> , 2022, 47, 309-319.	0.9	6
3	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 87-94.	0.4	259
4	Nephrology in the Czech Republic. , 2021, , 499-509.		0
5	Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. <i>Dermatologic Therapy</i> , 2021, 34, e14708.	0.8	2
6	Obstructive Jaundice Secondary to Pancreatic Head Metastasis of Malignant Amelanotic Melanoma as the First Clinical Manifestation. <i>Prague Medical Report</i> , 2021, 122, 45-51.	0.4	2
7	A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 8-13.	0.4	7
8	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	1.4	10
9	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.4	11
10	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients. <i>Metabolites</i> , 2021, 11, 774.	1.3	2
11	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 10-17.	0.4	38
12	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	6
13	Nephrology: achieving sustainability. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2030-2033.	0.4	10
14	Loss of bone mineral density and trabecular bone score in elderly hemodialysis patients: a 2-year follow-up, prospective, single-centre study. <i>International Urology and Nephrology</i> , 2020, 52, 379-385.	0.6	2
15	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	5.5	166
16	Dyslipidemia in patients with chronic kidney disease: etiology and management. <i>Vnitřní Lekarství</i> , 2020, 66, 275-281.	0.1	6
17	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 222-226.	0.4	2
18	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 393, 1937-1947.	6.3	408
20	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.4	27
21	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 4-6.	0.4	4
22	Biopically Proven "Anticoagulation-Related Nephropathy" Induced by Dual Antiplatelet Therapy. Case Reports in <i>Nephrology and Dialysis</i> , 2018, 8, 216-222.	0.3	6
23	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1077-1082.	0.4	4
24	FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSANTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i20-i20.	0.4	4
25	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 437-442.	1.4	1
26	Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study. <i>International Urology and Nephrology</i> , 2018, 50, 1721-1728.	0.6	10
27	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 901-903.	0.4	21
28	Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study. <i>Current Vascular Pharmacology</i> , 2018, 16, 298-305.	0.8	3
29	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. <i>Scientific Reports</i> , 2017, 7, 16915.	1.6	67
30	Anti" TGF- β 1 Antibody Therapy in Patients with Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 953-962.	3.0	203
31	Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1963-1966.	0.4	50
32	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016, 6, e010310.	0.8	103
33	Osteoporosis and Impaired Trabecular Bone Score in Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 345-354.	0.9	42
34	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	3.0	205
35	How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1605-1614.	0.4	121
36	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994"2011. <i>Journal of Nephrology</i> , 2015, 28, 39-49.	0.9	55

#	ARTICLE	IF	CITATIONS
37	Repeat protocol renal biopsy in ANCA-associated renal vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1728-1732.	0.4	31
38	The Intron 4 Polymorphism in the Calcium-Sensing Receptor Gene in Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 399-407.	0.9	5
39	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.4	106
40	Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-7.	0.6	38
41	What Is the Quality of Pre-Dialysis Healthcare in the Czech Republic. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 417-424.	0.9	1
42	Polymorphisms in the Vitamin D Receptor Gene and Parathyroid Hormone Gene in the Development and Progression of Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease. <i>Kidney and Blood Pressure Research</i> , 2012, 36, 1-9.	0.9	28
43	Gene polymorphisms in patients with type 2 diabetes and diabetic nephropathy. <i>Open Life Sciences</i> , 2012, 7, 210-218.	0.6	1
44	Clinical Manifestation and Natural History of Diabetic Nephropathy. <i>Contributions To Nephrology</i> , 2011, 170, 19-27.	1.1	86
45	Editorial. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 202-202.	0.9	1
46	Determination of Dialysis Dose: A Clinical Comparison of Methods. <i>Blood Purification</i> , 2011, 32, 271-277.	0.9	14
47	Contribution of Jan Brod to Nephrology. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 299-302.	0.9	1
48	Daily hemodialysis and caregivers burden. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2074-2076.	0.4	10
49	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. <i>PLoS ONE</i> , 2010, 5, e13421.	1.1	117
50	Renal disease and acute coronary syndrome. <i>Heart</i> , 2010, 96, 86-92.	1.2	17
51	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. <i>PLoS ONE</i> , 2010, 5, e13051.	1.1	51
52	Prevalence and Risk of Hypertension in Renal Disease – Data from the Czech Registry of Renal Biopsies. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 135-142.	0.9	5
53	Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 2-5.	0.9	1
54	NF- κ B and Its Inhibitor I κ B in Relation to Type 2 Diabetes and Its Microvascular and Atherosclerotic Complications. <i>Human Immunology</i> , 2006, 67, 706-713.	1.2	38

#	ARTICLE	IF	CITATIONS
55	Carnosine as a Protective Factor in Diabetic Nephropathy: Association With a Leucine Repeat of the Carnosinase Gene CNDP1. <i>Diabetes</i> , 2005, 54, 2320-2327.	0.3	264
56	Cystatin C as a Marker of Residual Renal Function during Continuous Hemodiafiltration. <i>Kidney and Blood Pressure Research</i> , 2005, 28, 14-19.	0.9	14
57	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3040-3049.	0.4	187
58	Transjugular Renal Biopsy. <i>Kidney and Blood Pressure Research</i> , 2001, 24, 207-212.	0.9	26
59	Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise?. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1550-1554.	0.4	27
60	LONG TERM TREATMENT OF IgA NEPHROPATHY WITH CYCLOSPORINE A. <i>Renal Failure</i> , 2000, 22, 55-62.	0.8	7
61	End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. <i>American Journal of Kidney Diseases</i> , 1999, 34, 795-808.	2.1	703
62	Endstage renal failure in diabetes type II - a silent epidemic. <i>Nephrology</i> , 1998, 4, 299-302.	0.7	2
63	The Influence of Pefloxacin on Experimental Adriamycin-Induced Nephrotic Syndrome in Rats. <i>Renal Failure</i> , 1996, 18, 195-199.	0.8	1
64	Diabetic Nephropathy – the Size of the Problem. , 0, , 1-17.		1